In 2023, Recursion Pharmaceuticals completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), and Scope 2 (indirect emissions from purchased energy).
However, Recursion Pharmaceuticals has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
---|---|---|---|---|
Total Scope 1 | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 2 | ||||
Market-Based | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Location-Based | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 3 | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
This table provides a simplified preview of selected GHG emissions data points. To access the complete dataset with full disclosures, detailed breakdowns, and source traceability, create a free account to view purchase options.
In 2023, the total operational greenhouse gas (GHG) emissions of Recursion Pharmaceuticals amounted to 2,718 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).
Compared to 2022, the total operational greenhouse gas (GHG) emissions of Recursion Pharmaceuticals increased by 117.61%, suggesting that the company faced challenges in reducing its emissions from its core operations.
In 2023, the total Scope 1 emissions of Recursion Pharmaceuticals were 854 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).
Compared to the previous year (2022), Recursion Pharmaceuticals's Scope 1 emissions increased by 217.47%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.
In 2023, Recursion Pharmaceuticals reported Scope 2 greenhouse gas (GHG) emissions of 1,474 tCOâ‚‚e using the market-based method, and 1,864 tCOâ‚‚e using the location-based method.
In 2023, Recursion Pharmaceuticals reported its Scope 2 emissions using the market-based method and using the location-based method.